RenovoRx, Inc. (RNXT) - חוב לטווח ארוך להון

RenovoRx, Inc. (RNXT) develops targeted toxin delivery systems for pancreatic cancer via the RenovoCath catheter. Intellectual property protection through patents exists alongside stringent safety requirements for clinical trials. The company is currently seeking partnerships with Big Pharma for commercialization. This chart of long-term debt load confirms these data, where the current parameter equals 0.03.

Identifying fundamentally resilient assets requires an analysis of the issuer's liability structure. This ratio compares the volume of loans with a maturity of over one year against equity, measuring the degree of long-term financial autonomy. For RenovoRx, Inc. (RNXT), which invests in robotic assembly lines for medical systems, this balance is critical when scaling production. A decrease in this metric confirms a strengthening balance sheet. By analyzing the trend of the long-term financial dependency ratio, an investor can objectively assess the reduction of credit risks.